Sichuan Xiongfei Litong Pharmaceutical Co. Ltd.

This study aimed to study the pharmacokinetic characteristics of a single fasting and postprandial oral administration of an oseltamivir phosphate dry suspension [6 mg/mL (as oseltamivir), packaging specification: 360 mg/bottle*1 bottle/box] developed and produced by Sichuan Ziren Pharmaceutical Co., Ltd.; using an oseltamivir phosphate dry suspension [TAMIFLU®, 6 mg/mL (as oseltamivir), packaging specification: 360 mg/bottle*1 bottle/box] produced by F. Hoffmann-La Roche AG as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

The pharmacokinetic parameters were used as the primary endpoint evaluation indicators to compare the pharmacokinetic behavior of the test preparation Olopatadine Hydrochloride Tablets provided by Sichuan Ziren Pharmaceutical Co., Ltd. and the reference preparation Olopatadine Hydrochloride Tablets (manufacturer: NIPRO PHARMA CORPORATION KAGAMIISHI PLANT) in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations. The safety of the test preparation Olopatadine Hydrochloride Tablets and the reference preparation Olopatadine Hydrochloride Tablets in healthy subjects was observed.